Market Summary

Introduction

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Human Immunodeficiency Virus (HIV1) Infection Market Overview – 8 Major Markets 

    3.1     Human Immunodeficiency Virus (HIV1) Infection Market Historical Value (2017-2023) 
    3.2     Human Immunodeficiency Virus (HIV1) Infection Market Forecast Value (2024-2032) 
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Human Immunodeficiency Virus (HIV1) Infection Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Treatment Pathway 
6    Patient Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Treatment Success Rate
7    Human Immunodeficiency Virus (HIV1) Infection Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    U.S.
            7.1.1.2    United Kingdom
            7.1.1.3    EU-4
            7.1.1.4    India
            7.1.1.5    Japan
        7.1.2    Diagnosed Cases, by Country
            7.1.2.1    U.S.
            7.1.2.2    United Kingdom
            7.1.2.3    EU-4
            7.1.2.4    India
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate, by Country 
            7.1.3.1    U.S.
            7.1.3.2    United Kingdom
            7.1.3.3    EU-4
            7.1.3.4    India
            7.1.3.5    Japan
8    Human Immunodeficiency Virus (HIV1) Infection Market Landscape – 8 Major Markets 
    8.1     Human Immunodeficiency Virus (HIV1) Infection Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2     Human Immunodeficiency Virus (HIV1) Infection Market: Product Landscape
        8.2.1    Analysis by Drug Class
        8.2.2    Analysis by Route of Administration
9    Human Immunodeficiency Virus (HIV1) Infection Market Challenges and Unmet Needs
    9.1    Treatment Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Treatment
11    Human Immunodeficiency Virus (HIV1) Infection Market Dynamics

    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political
        11.3.2    Economic
        11.3.3    Social
        11.3.4    Technological
        11.3.5    Legal
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends  
    11.8    Value Chain Analysis
12    Human Immunodeficiency Virus (HIV1) Infection Market Segmentation (2017-2032) - 8 Major Markets 
    12.1     Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Drug Class
        12.1.1    Market Overview
        12.1.2    Nucleoside-Analog Reverse Transcriptase Inhibitor
        12.1.3    Non-Nucleoside Reverse Transcriptase Inhibitor
        12.1.4    Protease Inhibitors
        12.1.5    Integrase Inhibitors
        12.1.6    Others
    12.2    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Route of Administration
        12.2.1    Market Overview
        12.2.2    Oral
        12.2.3    Parenteral
        12.2.4    Others 
    12.3    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by End User
        12.3.1    Market Overview
        12.3.2    Hospitals
        12.3.3    Homecare Settings
        12.3.4    Specialty Centers
        12.3.5    Others
    12.4    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Distribution Channel
        12.4.1    Market Overview
        12.4.2    Hospital Pharmacies
        12.4.3    Independent Pharmacies
        12.4.4    Others 
    12.5    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Region
        12.5.1    Market Overview
        12.5.2    United States
        12.5.3    EU-4 and the United Kingdom
            12.5.3.1    Germany
            12.5.3.2    France
            12.5.3.3    Italy
            12.5.3.4    Spain
            12.5.3.5    United Kingdom
        12.5.4    India
        12.5.5    Japan
13    United States Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032)
    13.1    United States Human Immunodeficiency Virus (HIV1) Infection Market Historical Value (2017-2023) 
    13.2    United States Human Immunodeficiency Virus (HIV1) Infection Market Forecast Value (2024-2032)
    13.3    United States Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Drug Class
        13.3.1    Market Overview
        13.3.2    Nucleoside-Analog Reverse Transcriptase Inhibitor
        13.3.3    Non-Nucleoside Reverse Transcriptase Inhibitor
        13.3.4    Protease Inhibitors
        13.3.5    Integrase Inhibitors
        13.3.6    Others
    13.4    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Route of Administration
        13.4.1    Market Overview
        13.4.2    Oral
        13.4.3    Parenteral
        13.4.4    Others 
    13.5    United States Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by End User
        13.5.1    Market Overview
        13.5.2    Hospitals
        13.5.3    Homecare Settings
        13.5.4    Specialty Centers
        13.5.5    Others
    13.6    United States Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Distribution Channel
        13.6.1    Market Overview
        13.6.2    Hospital Pharmacies
        13.6.3    Independent Pharmacies
        13.6.4    Others
14    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032)
    14.1    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market Historical Value (2017-2023) 
    14.2    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Drug Class
        14.3.1    Market Overview
        14.3.2    Nucleoside-Analog Reverse Transcriptase Inhibitor
        14.3.3    Non-Nucleoside Reverse Transcriptase Inhibitor
        14.3.4    Protease Inhibitors
        14.3.5    Integrase Inhibitors
        14.3.6    Others
    14.4    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Route of Administration
        14.4.1    Market Overview
        14.4.2    Oral
        14.4.3    Parenteral
        14.4.4    Others 
    14.5    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by End User
        14.5.1    Market Overview
        14.5.2    Hospitals
        14.5.3    Homecare Settings
        14.5.4    Specialty Centers
        14.5.5    Others
    14.6    EU-4 and United Kingdom Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Distribution Channel
        14.6.1    Market Overview
        14.6.2    Hospital Pharmacies
        14.6.3    Independent Pharmacies
        14.6.4    Others
15    India Human Immunodeficiency Virus (HIV1) Infection Market
    15.1    India Human Immunodeficiency Virus (HIV1) Infection Market Historical Value (2017-2023) 
    15.2    India Human Immunodeficiency Virus (HIV1) Infection Market Forecast Value (2024-2032)
    15.3    India Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Drug Class
        15.3.1    Market Overview
        15.3.2    Nucleoside-Analog Reverse Transcriptase Inhibitor
        15.3.3    Non-Nucleoside Reverse Transcriptase Inhibitor
        15.3.4    Protease Inhibitors
        15.3.5    Integrase Inhibitors
        15.3.6    Others
    15.4    Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Route of Administration
        15.4.1    Market Overview
        15.4.2    Oral
        15.4.3    Parenteral
        15.4.4    Others 
    15.5    India Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by End User
        15.5.1    Market Overview
        15.5.2    Hospitals
        15.5.3    Homecare Settings
        15.5.4    Specialty Centers
        15.5.5    Others
    15.6    India Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Distribution Channel
        15.6.1    Market Overview
        15.6.2    Hospital Pharmacies
        15.6.3    Independent Pharmacies
        15.6.4    Others
16    Japan Human Immunodeficiency Virus (HIV1) Infection Market
    16.1    Japan Human Immunodeficiency Virus (HIV1) Infection Market Historical Value (2017-2023) 
    16.2    Japan Human Immunodeficiency Virus (HIV1) Infection Market Forecast Value (2024-2032)
    16.3    Japan Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Drug Class
        16.3.1    Market Overview
        16.3.2    Nucleoside-Analog Reverse Transcriptase Inhibitor
        16.3.3    Non-Nucleoside Reverse Transcriptase Inhibitor
        16.3.4    Protease Inhibitors
        16.3.5    Integrase Inhibitors
        16.3.6    Others
    16.4     Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Route of Administration
        16.4.1    Market Overview
        16.4.2    Oral
        16.4.3    Parenteral
        16.4.4    Others
    16.5    Japan Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by End User
        16.5.1    Market Overview
        16.5.2    Hospitals
        16.5.3    Homecare Settings
        16.5.4    Specialty Centers
        16.5.5    Others
    16.6    Japan Human Immunodeficiency Virus (HIV1) Infection Market (2017-2032) by Distribution Channel
        16.6.1    Market Overview
        16.6.2    Hospital Pharmacies
        16.6.3    Independent Pharmacies
        16.6.4    Others
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    India CDSCO
    17.5    Japan PMDA
18    Patent Analysis
    18.1    Analysis by Drug Class of Patent
    18.2    Analysis by Publication Year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by Year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Distribution Channel
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Drug Class of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Strategic Initiatives
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Drug Class of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Market Share by Top 5 Companies
    23.2    Cipla 
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Company News and Development
        23.2.5    Certifications
    23.3    Genentech Inc. 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Company News and Development
        23.3.5    Certifications
    23.4    Gilead Sciences Inc. 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Company News and Development
        23.4.5    Certifications
    23.5    AbbVie Inc 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Company News and Development
        23.5.5    Certifications
    23.6     Boehringer Ingelheim International GmbH 
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Company News and Development
        23.6.5    Certifications
    23.7    ViiV Healthcare  
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Company News and Development
        23.7.5    Certifications
    23.8    Sanofi 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Company News and Development
        23.8.5    Certifications
    23.9    Bristol Myers Squibb 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Company News and Development
        23.9.5    Certifications
24    Human Immunodeficiency Virus (HIV1) Infection Treatment Drugs - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)

    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

    
*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

 

*Additional insights provided are customizable as per client requirements.

*The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

*The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124